QURE News and Press, uniQure N.V. From 02/17/26

2026-02-17 02:14:00 ET ... Read the full article on Seeking Alpha For further details see: Diamond Hill International Strategy Q4 2025 Portfolio Review

The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. ...

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). uniQure is a biotechnology company. For...

~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discont...

2026-01-29 13:22:00 ET The following segment was excerpted from the Alger Small Cap Focus Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Alger Small Cap Focus Fund Q4 2025 Portfolio Update

2026-01-27 17:04:48 ET from Barclays issued a price target of $31.00 for QURE on 2026-01-27 21:31:13. The adjusted price target was set to $31.00. At the time of the announcement, QURE was trading at $24.37. The overall price target consensus is at $55.67 with high price...

Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Sign...

2026-01-09 08:05:17 ET More on uniQure uniQure: Now What? uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside uniQure stock falls after FDA's notes on pre application of AMT...

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been sch...

2026-01-08 15:36:35 ET Overview In my last uniQure ( QURE ) write-up , the company was preparing to launch AMT-130, a gene therapy, for Huntington’s disease, or HD.... Read the full article on Seeking Alpha For further details see: uniQure: Now What?